Investor Relations
Transparent management. Sustainable growth.
Boostree is a B2B infrastructure group building the digital infrastructure of Korea’s aesthetic-medicine industry. As we prepare for an initial public offering (IPO), we will share our progress openly along the way.
- IPO target
- 2029
- Partner clinics
- 200+
- Partners using multiple services
- 75%+
Photo · 4:5
Key Investment Points
Why Boostree
-
Growth aligned with our partners
Our revenue grows only when our partner clinics grow. Our results come from our partners’ growth, not from short-term fees.
-
Multi-service adoption
More than 75% of our partners use two or more of our services. Once a partner is connected, the connection deepens.
-
Korea’s only full-stack infrastructure
From clinic launch consulting to management, marketing, payments, procurement, training and CX — Boostree is the only full-stack infrastructure built specifically for aesthetic medicine.
Governance
Group structure
주식회사 부스트리 (Boostree Inc.), the parent company, runs its business units directly and holds Bemytree as a wholly owned (100%) subsidiary.
-
Parent company
주식회사 부스트리 (Boostree Inc.)
MSO · SaaS · MRO · CX · Dermanode Lab
-
100% subsidiary
주식회사 비마이트리 (Bemytree Inc.)
Personal branding and marketing for clinics
Disclosures
Disclosures
We will publish disclosures on this page step by step, in line with our external audit and listing preparation schedule. There are no public disclosures yet.
Financials
Financial information
We will publish financial highlights once our audit report is finalized. Investors who need detailed materials are welcome to request them from our IR contact.
IR Library
IR library
Our company profile and IR materials are available on request. We will add materials here as they become available for public release.
Let us know what you need for your investment review, and we will get back to you once we have looked at your request.
contact@boostree.partners